Profit before tax (PBT) climbed 22.52% YoY to Rs 17.68 crore in Q1 FY27.

Operating EBITDA rose 21.4% YoY to Rs 19.1 crore from Rs 15.7 crore in Q1 FY26. EBITDA margin expanded to 23.2% from 20.8% a year earlier, supported by operating leverage driven by improved medical representative (MR) productivity.

The company also highlighted the integration of Aequitas, which has a revenue base of Rs 53.3 crore. Management expects the acquisition to contribute to higher revenue and profitability from the second half of FY27 and is targeting EBITDA of more than Rs 10 crore by the second year after integration.

Manish Gupta, managing director and CEO, Jagsonpal Pharmaceuticals, said, “Q1FY27 reflects sustained traction in our business, with revenue growing 9% YoY, driven by higher MR productivity and continued strength across our key brands. We significantly outperformed the industry, with Pharmarack reporting 18.9% growth for Jagsonpal versus 11.6% for the IPM, leading to a 4 ranks improvement to #88 in the Indian pharmaceutical market.

We recently completed the acquisition of a controlling stake (85%) in Aequitas Healthcare, marking our entry into the hospital supplies segment. We also concluded our Rs 40 crore share buyback resulting in an ROCE improvement by 340 bps. Even with these capital allocation initiatives, we ended the quarter with a healthy cash balance of Rs 170 crore.

With a stronger business franchise, disciplined capital allocation, and multiple growth levers in place, we remain confident of sustaining profitable growth while pursuing value-accretive inorganic opportunities.”

Jagsonpal Pharmaceuticals has portfolio of drugs focusing on gynaecology, orthopaedics, dermatology and child-care segments.